Eine Phase -II -Studie zur Bewertung der klinischen Wirksamkeit, Sicherheit und Verträglichkeit von MAS825 bei pädiatrischen und erwachsenen Teilnehmern mit Still -Krankheit
Eine Open-Label-Phase-II-Studie zur Bewertung der klinischen Wirksamkeit, Sicherheit und Verträglichkeit von MAS825 bei pädiatrischen und erwachsenen Teilnehmern mit Still-Krankheit
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
Studienübersicht
Detaillierte Beschreibung
This is a multicenter, open-label, single-arm study to assess clinical efficacy, safety and tolerability of MAS825 in participants (both pediatric and adult) with Still's disease who have had inadequate response to IL-1 and/or IL-6 or other available therapies. Participants with associated lung disease and/or macrophage activation syndrome may also be included.
This study has three periods (Screening, Treatment Period 1, and Treatment Period 2) and a total duration of approximately 16 months.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Novartis Pharmaceuticals
- Telefonnummer: 1-888-669-6682
- E-Mail: novartis.email@novartis.com
Studieren Sie die Kontaktsicherung
- Name: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
Studienorte
-
-
-
Heidelberg, Deutschland, 69120
- Rekrutierung
- Novartis Investigative Site
-
Münster, Deutschland, 48149
- Rekrutierung
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Sankt Augustin, North Rhine-Westphalia, Deutschland, 53757
- Rekrutierung
- Novartis Investigative Site
-
-
-
-
-
Bordeaux, Frankreich, 33076
- Rekrutierung
- Novartis Investigative Site
-
Bron, Frankreich, 69677
- Rekrutierung
- Novartis Investigative Site
-
Le Kremlin-Bicêtre, Frankreich, 94275
- Rekrutierung
- Novartis Investigative Site
-
Lille, Frankreich, 59037
- Rekrutierung
- Novartis Investigative Site
-
Paris, Frankreich, 75015
- Rekrutierung
- Novartis Investigative Site
-
Paris, Frankreich, 75970
- Rekrutierung
- Novartis Investigative Site
-
-
-
-
FI
-
Florence, FI, Italien, 50139
- Rekrutierung
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italien, 16147
- Rekrutierung
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italien, 00165
- Rekrutierung
- Novartis Investigative Site
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- Rekrutierung
- Novartis Investigative Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H4A 3J1
- Zurückgezogen
- Novartis Investigative Site
-
Montreal, Quebec, Kanada, H3T 1C5
- Zurückgezogen
- Novartis Investigative Site
-
-
-
-
-
Utrecht, Niederlande, 3584 CX
- Aktiv, nicht rekrutierend
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spanien, 28046
- Rekrutierung
- Novartis Investigative Site
-
Valencia, Spanien, 46026
- Rekrutierung
- Novartis Investigative Site
-
-
Barcelona
-
Esplugues, Barcelona, Spanien, 08950
- Rekrutierung
- Novartis Investigative Site
-
-
-
-
Fatih
-
Istanbul, Fatih, Türkei (türkiye), 34098
- Rekrutierung
- Novartis Investigative Site
-
-
Sihhiye Altindag
-
Ankara, Sihhiye Altindag, Türkei (türkiye), 06230
- Rekrutierung
- Novartis Investigative Site
-
-
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Aktiv, nicht rekrutierend
- Cincinnati Childrens Hospital
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97232
- Rekrutierung
- Legacy Emanuel Research Hosp Portland
-
Hauptermittler:
- Daniel Joseph Kingsbury
-
Kontakt:
- Brenna Bogle
- Telefonnummer: +1 503 413 5447
- E-Mail: bbogle@lhs.org
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84113
- Rekrutierung
- University of Utah
-
Kontakt:
- Tressie Rollins
- Telefonnummer: +1 415 515 8212
- E-Mail: tressie.rollins@hsc.utah.edu
-
Hauptermittler:
- Aimee Ogden Hersh
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Age ≥ 1 with a diagnosis of Still's Disease
-
Active diseases defined as:
-
CRP or ferritin levels greater than ULN, and any of:
- Fever ≥ 38°C attributed to Still's Disease activity and documented for a number of days prior to Day 1 or
- Rash attributed to Still's Disease activity or
- Musculoskeletal involvement: arthritis in a number of joints per ACP criteria for active joint or
- Serositis or
- Macrophage activation syndrome activity as defined by ferritin levels and at least one of: platelet count, a biomarker or fibrinogen levels attributed to Still's Disease activity by the investigator
-
Intolerance or inadequate response to available biologic therapy
Exclusion Criteria:
-
Patients out of weight range
-
Ongoing or previous treatment with immunomodulatory drugs
- A limited number of Still's Disease patients that have previously received MAS825 through a managed access program are permitted on the study
-
Glucocorticoid dose exceeding a set limit
-
Any conditions or significant medical problems which places the patient at unacceptable risk for MAS825 therapy
- Still's disease patients with evidence of macrophage activation syndrome are permitted in the study
- Still's Disease patients with evidence of interstitial lung disease including those requiring supplemental oxygen therapy are permitted in the study
-
History of ongoing, chronic or possibly recurrent infection (e.g. HIV, TB, HCV, HBV) and/or symptoms and signs of clinically significant active bacterial, fungal or viral infections
-
Live vaccinations within a set time prior to MAS825 treatment. Live vaccines are prohibited up to several months following the last dose
-
History of malignancy of any organ system, including post-transplant lymphoproliferative disorder, treated or untreated, within a number of years, regardless of whether there is evidence of local recurrence and metastases
-
History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or to any of the excipients
-
Pregnant or breastfeeding women
-
Women of child-bearing potential who do not agree to comply with required contraceptive use
Other protocol-defined inclusion/exclusion criteria may apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: MAS825
Experimental drug |
Experimental drug
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants with clinical response based on one set of response criteria
Zeitfenster: Day 85
|
Established measure for efficacy of treatments in the rheumatologic conditions taking into account self-assessment, function and survival. |
Day 85
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants with clinical response based on another set of response criteria
Zeitfenster: Day 85
|
Established measure for efficacy of treatments in the rheumatologic conditions taking into account self-assessment, function and survival. |
Day 85
|
|
Response based on a biomarker level
Zeitfenster: Baseline, Day 85
|
To evaluate the efficacy of MAS825 in reducing clinical disease activity |
Baseline, Day 85
|
|
Change in physician assessment based on laboratory features of MAS825
Zeitfenster: Baseline, 15 months
|
To assess the effect of MAS825 on macrophage activation syndrome |
Baseline, 15 months
|
|
Change from baseline in Glucocorticoid (GC) dose
Zeitfenster: Baseline, Day 85, Month 6, Month 12
|
To evaluate the efficacy of MAS825 as a glucocorticoid-sparing agent |
Baseline, Day 85, Month 6, Month 12
|
|
Change from baseline in patient/parent assessment of physical function as assessed by Quality of Life instrument
Zeitfenster: Baseline, Day 85
|
To evaluate the efficacy of MAS825 in improving participant's quality of life |
Baseline, Day 85
|
|
Clinically inactive disease whilst on non-treatment dose corticosteroid at any time during the study
Zeitfenster: 15 months
|
The number of participants with inactive disease will be assessed. Disease activity will be evaluated by the investigator based on physical examination and laboratory parameters. Inactive disease is defined according to protocol-specific criteria, which include clinical signs, laboratory values, and physician assessment. |
15 months
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CMAS825J12201
- 2024-520208-25-00 (Andere Kennung: EU CT Number)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .